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IntroductIon
Chronic mountain sickness (CMS) or Monge’s disease oc-
curs in up to 20% of individuals residing at high altitude 
in various regions of the world (León-Velarde et al., 2000; 
Mejía et al., 2005; Wu, 2005; Jiang et al., 2014). Three large 
high-altitude populations (Andeans, Ethiopians, and Tibet-
ans) have been extensively studied (Beall, 2000, 2006; Zhou 
et al., 2013; Udpa et al., 2014), and these have provided a 
unique opportunity to investigate the mechanisms of adap-
tation to high-altitude hypoxia and evolution because these 
human populations have been under selection pressure for 
centuries (Beall, 2000, 2006; Zhou et al., 2013; Udpa et al., 
2014). For Tibetans, EGLN1, EPAS1, and PPARα have seem-
ingly been under positive selection as illustrated in multiple 
studies (Simonson et al., 2010; Xiang et al., 2013; Lorenzo et 
al., 2014; Luo et al., 2014). In the Andean population, several 
studies, including our own, have pointed out that there are 
several candidate genes, such as ANP32D, SENP1, G allele 
NOS3, and vascular endothelial growth factor (VEGF) loci, 
that likely play a role (Appenzeller et al., 2006; León-Velarde 
and Mejía, 2008; Zhou et al., 2013). In Ethiopian highland-
ers, CBA RA1, VAV3, ARNT2, and THRB, CIC, LIPE, and 
PAF AHIB3 have been linked to adaptation (Alkorta-Aran-
buru et al., 2012; Scheinfeldt et al., 2012; Udpa et al., 2014; 
Gonzales and Chaupis, 2015). It is important to note that 
some of these DNA-selected regions and candidate genes, as 
in our previous studies (Zhou et al., 2013; Udpa et al., 2014), 
have been shown to be causally related to the phenotype of 
tolerance to high-altitude hypoxia. Furthermore, hypoxia- 
inducible factor (HIF) can certainly play an important role in 
hypoxia adaptation as has been shown by several investigators 
(Ronen et al., 2014). Such studies demonstrate the complex 
and multilocus adaptation to hypoxia and indicate that differ-
ent populations might adapt by using different mechanisms 
or routes (Ronen et al., 2014). Besides these genotypic differ-
ences among these three populations, there exist differences 
also in terms of phenotypic adaptive responses, such as resting 
ventilation, hypoxic ventilatory response, oxygen saturation, 
and hemoglobin concentration (Beall, 2006).
Excessive polycythemia is one of the critical aspects of 
Monge’s disease (Monge et al., 1965; Monge-C et al., 1992). 
Although it can be argued that polycythemia in CMS subjects 
could be advantageous at high altitude because an increase in 
hemoglobin increases O2-carrying capacity theoretically, this 
adaptive trait has deleterious effects because blood increases 
its viscosity, which, in turn, induces serious morbidities such 
In this study, because excessive polycythemia is a predominant trait in some high-altitude dwellers (chronic mountain sickness 
[cMS] or Monge’s disease) but not others living at the same altitude in the Andes, we took advantage of this human experi-
ment of nature and used a combination of induced pluripotent stem cell technology, genomics, and molecular biology in this 
unique population to understand the molecular basis for hypoxia-induced excessive polycythemia. As compared with sea-level 
controls and non-cMS subjects who responded to hypoxia by increasing their rBcs modestly or not at all, respectively, cMS 
cells increased theirs remarkably (up to 60-fold). Although there was a switch from fetal to adult HgbA0 in all populations 
and a concomitant shift in oxygen binding, we found that cMS cells matured faster and had a higher efficiency and prolifer-
ative potential than non-cMS cells. We also established that SEnP1 plays a critical role in the differential erythropoietic 
response of cMS and non-cMS subjects: we can convert the cMS phenotype into that of non-cMS and vice versa by altering 
SEnP1 levels. We also demonstrated that GAtA1 is an essential downstream target of SEnP1 and that the differential expres-
sion and response of GAtA1 and Bcl-xL are a key mechanism underlying cMS pathology.
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as myocardial infarction and stroke (DeFilippis and Aaberg, 
2003; Jansen and Basnyat, 2011). This is often the case in 
these subjects, in addition to pulmonary hypertension, right 
heart hypertrophy, and ultimately cardiac failure (Penaloza 
and Arias-Stella, 2007; Naeije, 2010; Naeije and Vanderpool, 
2013). The only and inadequate treatment for these patients 
is periodic phlebotomy.
The high heritability for hemoglobin concentration in 
the Andean population suggests that it is under natural selec-
tion (Beall, 2006). Although erythropoietin (EPO) is consid-
ered to be a major regulator of RBC production, the role of 
EPO in excessive erythropoiesis, particularly in the Andes, is 
so far inconclusive (León-Velarde et al., 1991; Franke et al., 
2013; Haase, 2013). For example, studies in Peru and Bolivia 
(La Paz) have shown that some residents develop excessive 
polycythemia despite having similar serum EPO values at the 
same elevation of healthy highlanders (Dainiak et al., 1989; 
León-Velarde et al., 1991). These studies would suggest that 
EPO most likely continues to play a critical role in eryth-
ropoiesis at high altitude, and hence, further studies are re-
quired to understand its interaction with other genetic loci, 
which leads to excessive polycythemia. Furthermore, genetic 
approaches did not reveal any evidence of an association be-
tween EPO or EPOR gene polymorphisms and polycythe-
mia (Mejía et al., 2005). This suggested to us that there must 
be other possible mechanisms that play an important role in 
excessive erythropoiesis in high-altitude Andean polycythe-
mia. One major reason for our interest in this extreme phe-
notype is that we hypothesize that the molecular mechanisms 
that are underlying this phenotype may teach us about other 
related diseases at sea level or about protection of tissues when 
they are hypoxic or ischemic, as we have recently shown from 
studies at high altitude (Stobdan et al., 2015).
rESuLtS
Generation of human induced pluripotent stem cells (iPScs) 
from cMS and non-cMS subjects followed by in vitro 
erythroid differentiation
To understand the genetic basis of CMS, we acquired blood 
samples as well as skin biopsies from the same individu-
als (CMS and non-CMS) residing in Peru (∼4338 m; cor-
responding to ∼59% of O2 at sea level). We sequenced the 
whole genomes from 20 subjects (10 individuals with CMS 
and non-CMS) and reported on these in a previous study 
(Zhou et al., 2013). We have now reprogrammed fibro-
blasts and generated human iPSCs from five CMS and four 
non-CMS subjects (Table 1), as well as from three sea-level 
subjects used as controls. The iPSCs were characterized using 
DNA fingerprinting, high-resolution karyotyping, and alka-
line phosphatase staining, as well as assessing the expression of 
multilineage differentiation markers, as described in detail in 
the Characterization of iPSCs section of Materials and meth-
ods as well as in our previous work (Zhao et al., 2015). DNA 
fingerprinting analysis confirmed that the iPSC lines were 
identical to parental fibroblast lines. The reprogramming of 
iPSCs was confirmed by staining for pluripotency markers 
and alkaline phosphatase and the ability to differentiate into 
three germ layers in vitro (Zhao et al., 2015). The expression 
of transgenes in the mRNA of iPSCs was low or undetect-
able, and stem array confirmed that the karyotypes of iPSC 
colonies were normal (Zhao et al., 2015).
We transformed iPSC lines into erythroid cells (refer to 
the Erythroid induction and differentiation section of Materi-
als and methods) by adopting a previously published protocol 
(Kobari et al., 2012). We used sequential cytokines mixtures 
for induction and maturation of erythroid population, as pre-
viously described (Fig. 1 A; Kobari et al., 2012). A quanti-
tative assessment was performed of surface markers such as 
CD34, CD45 (leukocyte common antigen), CD71 (transfer-
rin receptor protein 1), CD36, and CD235a (glycophorin A). 
Fig. 1 B shows the CD profile under normoxic conditions, 
including the gradual increase of CD71 and its subsequent 
fall and the increase in CD235a with time. Sturgeon et al. 
(2014) have shown that primitive hematopoietic progenitors 
are KDR (kinase insert domain receptor)+CD235a+, but we 
believe that CD235a represents erythroid lineage in our stud-
ies because their appearance is late in maturation, and this 
correlates with the timing of hemoglobinization. At earlier 
stages, CD34 and CD45 increase and then decrease, as ex-
pected. The protocol is ∼8 wk long for differentiation and 
maturation of RBCs, and after 8 wk, all populations show 
∼99.9% are CD235a-positive cells (Fig. 1, A and B). These 
CD patterns were observed under normoxia in all three pop-
ulations as shown in Fig. 1 B, Fig. 2, and Fig. 3 A. To de-
termine the effect of hypoxia, we altered this procedure by 
exposing cells either to hypoxia or normoxia at the embryoid 
body (EB) stage and studied the differences among CMS and 
non-CMS cells (Fig. 2).
replicating the disease in the dish: Marked differences 
between cMS and non-cMS cells in response to hypoxia
To emulate high-altitude hypoxia, we exposed cells to 5% O2 
(Fig. 2) for 3 wk at the EB stage (after 1 wk in normoxia, as 
described in the legend of Fig. 1). We measured the response 
of the cells to hypoxia on day 28 by FACS using CD235a as 
an erythroid marker. Fig. 2 shows a remarkable difference in 
response to hypoxia among the three different groups. On the 
one hand, sea-level subjects increased the relative proportion 
of CD235a cells modestly, as expected (by ∼7%), whereas the 
non-CMS group did not respond to hypoxia at all with a rel-
ative proportion of ∼0.5% CD235a cells. On the other hand, 
CMS subjects had a marked response, increasing to ∼57%, 
corresponding to a huge increase of many folds (Fig. 2). Fig. 2 
(A and B) shows the robust response of each of the CMS (n = 
5), non-CMS (n = 4), and sea-level (n = 3) subjects (***, P < 
0.001; one-way ANO VA with Tukey posthoc analysis). Fur-
thermore, to determine interclonal variability, we have now 
tested three clones for each of the three subjects in each group 
under hypoxia (Fig. 2 C). The interclonal variability among 
the clones for each group is not significant as determined by 
2731JEM Vol. 213, No. 12
one-way ANO VA (P = 0.99; Fig. 2 C). The variability among 
the clones for each subject was 5–10%, whereas the smallest 
difference between the groups was 5–10-fold. In addition, we 
also used the pooling method of Chou et al. (2015) (n = 
20–25 clones) for each of the groups: CMS, non-CMS, and 
sea level (Chou et al., 2015). As expected, we also observed 
that the erythropoietic response of CMS under hypoxia is 
remarkably and significantly higher than both the non-CMS 
and sea-level control groups (relative proportion of CD235a 
being on average 72 ± 13.7 in CMS cells and 0.78 ± 0.2 in 
non-CMS cells; not depicted). Hence, we conclude that the 
polycythemic response of CMS is genetic in nature, and clonal 
variability is minimal as compared with the robust phenotype.
This in vitro experiment replicated the high-alti-
tude in vivo response of the three populations. In addition, 
we have now used footprint-free Sendai technology and 
retroviral vectors to generate iPSCs. With these Sendai- 
generated iPSCs, we observed a similar pattern of phenotypic 
differences in hypoxia: an exuberant response in CMS and a 
blunted one in non-CMS cells (Fig. 2 A). These results in our 
subject-specific iPSC lines strongly suggest a genetic basis of 
the polycythemia in the Andean population. To build a dose 
response and because there was such a large response to 5% 
O2 in CMS cells, we elected to expose cells to other levels of 
hypoxia (10% and 1.5%). Fig. 2 D shows the differential sensi-
tivity of the three populations to graded hypoxia, with a huge 
sensitivity to hypoxia in cells from CMS subjects.
We next defined the functional and maturational char-
acteristics of the erythroid lineage in the three populations 
by performing (a) assessment of surface markers and mem-
brane proteins, (b) colony-forming potential, (c) efficiency 
of differentiation, (d) hemoglobin pattern, and (e) oxygen- 
binding affinity. Under normoxia, CD profiles (CD45, CD71, 
and CD235a) at each week were not statistically significantly 
different between the groups (sea level, non-CMS, and CMS; 
Fig. 3 A). However, we observed dramatic differences in the 
maturational CD profile when we compared CMS and non-
CMS cells in hypoxia (Fig. 3 B and Table 2). After 3 wk of 
hypoxic exposure, the relative proportion of CD235a+ cells 
was 50–60% in CMS cells, whereas this proportion was <5% 
of cells in non-CMS subjects (Fig. 3 B). CMS cells also pro-
duced significantly higher number of erythroid burst-form-
ing units (BFU-Es; fourfold) as compared with non-CMS 
cells (Fig. 3 C), suggesting that the erythroid progenitors in 
the CMS population have a higher proliferative potential 
than the non-CMS population. Table  2 shows the amplifi-
cation potential for all three groups: although all groups had 
similar rates of erythroid production in normoxia, CMS cells 
produced a higher proportion of EBs as well as erythroid cells 
in hypoxia (Table 2). Our results indicate that hypoxia affects 
both proliferation as well as maturation of CMS cells (but not 
the other populations), as we observed differences in both 
the number of cells as EBs and BFU-Es as well as changes 
in CD markers. By performing hemoglobin analysis, we also 
observed a switch from fetal to adult HgbA0 starting at week Ta
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6 of differentiation of iPSCs (Fig. 3, D and F). Indeed, there 
was an increase in the proportion of adult HgbA0 (an increase 
in α and β globin expression) and a decrease in expression of ε 
and γ (Fig. 3 F). Concomitantly, there was a shift in P50 from 
14 mmHg to 22 mmHg (Fig. 3 D), consistent with matura-
tion of RBC function in vivo. Furthermore, during eryth-
roid maturation, band3 (HCO3-Cl transporter) and Glut1 
appeared in all cell populations (Fig. 3 E).
Based on our previous findings of whole-genome se-
quencing of CMS and non-CMS subjects, we then studied 
the role of one of the candidate genes that we mined from 
our detailed analysis (Zhou et al., 2013). In addition, we per-
formed a reduction experiment to investigate the role of 
various known cytokines presumed to be essential for eryth-
ropoiesis to probe at potential pathways involved in RBC 
formation in each of the three populations (refer to the Re-
duction experiment for cytokines [SCF, TPO, FLT3, BMP4, 
VEGF, IL3, IL6, and EPO] section of Materials and methods).
critical role of SEnP1 in polycythemia
SENP1 is a small ubiquitin-like modifier (SUMO) protease that 
cleaves SUMO groups off of several targets, including GATA1 
and HIF1 (Cheng et al., 2007). Fig.  4  A shows 66 single-
nucleotide polymorphisms (SNPs) identified as significantly 
divergent in allele frequency between CMS and non-CMS 
individuals (differential SNPs). Three of these differential 
SNPs (SNP accession nos. rs74910025, rs12581972, and 
rs726354) are in the cluster of ENC ODE (The Encyclopedia 
of DNA Elements) transcription factor–binding sites 
(ENC ODE Project Consortium, 2012; Rosenbloom et al., 
2012). This site (chr12 :48500334; rs726354) also overlaps a 
DNase I–hypersensitive region observed mainly in blood cells 
(Sabo et al., 2004). Furthermore, they also overlap with different 
regulatory regions: chr12 :48500334 (rs726354) overlaps with 
the promoter site, chr12 :48478354 (rs12581972) overlaps with 
one of the CTCF sites, and chr12 :48472343 (rs74910025) 
overlaps with one of the enhancer sites (Fig. 4 A). It is interesting 
to note that the differential SNP rs726354 coincides with 
binding sites of transcriptional factors such as E2F1, POLR2A, 
GAB PA, TAF1, ELF1, and GATA1. Another independent 
study from the Andean cohorts from Cerro de Pasco consisting 
of 84 CMS cases and 91 healthy controls reproduced and 
validated our previous results for divergent SNPs in the SENP1 
region (Cole et al., 2014). We therefore hypothesized that the 
differential SNPs in the regulatory regions alter the expression 
of SENP1 in CMS or non-CMS subjects. Indeed, when we 
compared the transcriptional response of CMS to that of non-
CMS cells in hypoxia, we found that CMS cells up-regulated 
SENP1, suggesting that this up-regulation could underlie the 
excessive erythrocytosis present in the CMS population (Zhou 
et al., 2013). We have indeed observed a significant increase 
not only in SENP1 mRNA, but also at the protein level in 
Figure 1. Production of erythroid cells 
from human iPSc. (A) Schematic representa-
tion of the successive culture steps for produc-
tion of cultured RBCs (cRBCs) from fibroblasts. 
Fibroblasts were transformed to iPSCs using 
the Yamanaka factors. Clumps of undifferenti-
ated iPSCs were cultured in erythroid body (EB) 
medium for 28 d in the presence of a mixture 
of cytokines (cytokine profile 1). After 1 wk of 
culturing in normoxia, erythroid bodies were 
allowed to differentiate for 3 wk in normoxia/
hypoxia, and the populations were analyzed 
by flow cytometry at day 28 or were allowed 
to mature further under cytokine profile 2 by 
sequential sets of cocktails and analyzed at 
day 58. Bars: (fibroblasts) 200 µm; (iPSC) 200 
µm; (EB) 200 µm; (red blood cell, right) 2 µm. 
(B) CD analysis of various CD markers (CD34, 
CD45, CD36, CD71, and CD235a) under nor-
moxia for sea-level samples. Each experiment 
was done in three replicates, and the experi-
ment was done at least three times. The cells 
are cultured as erythroid bodies in cytokine 
profile 1 and as single cells in cytokine profile 
2 (sequential mixture of cytokines). Error bars 
represent the mean ± SEM of at least two to 
three measurements. The experiment was re-
peated at least three times.
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CMS subjects under hypoxia (P < 0.05; Fig. 4 B). This notion 
is strengthened by previous studies demonstrating that SENP1 
regulates erythropoiesis and that SENP1−/− mouse embryos 
die of anemia (Yu et al., 2010).
To determine whether SENP1 plays an important role 
in the exuberant response to hypoxia in CMS subjects, we 
generated a lentiviral vector to down-regulate SENP1in CMS 
iPSCs. There was a significant reduction of SENP1 in the 
shRNAi-generated clones at both the mRNA and protein 
levels (Fig. 4, C and D). With SENP1 shRNAi, the relative 
proportion of CD235a fell remarkably to <1%, as compared 
with a mean (n = 3) of ∼60% observed in noninfected CMS 
Figure 2. Hypoxic response of sea-level, non-cMS, and cMS cells: Marked response of cMS samples. (A) Flow cytometric analysis using CD235a 
(glycophorin A) as a marker after culturing as detailed in Fig. 1 at the EB stage at day 28. Sendai virus results: Representative FACS plots of sea level, non-
CMS, and CMS in normoxia (left) and in hypoxia (right). The dot plot represents the live cells as gated through propidium iodide. CD235a+ cells are shown in 
red along the y axis, and CD235a− cells are shown in blue. The percentage in each figure represents the relative proportion of CD235a cells. There are major 
differences between CMS (bottom) versus the non-CMS (middle) and sea-level (top) samples. The FACS plots are representative of one experiment. Similar 
results were obtained in all the experimental repeats. (B) Summary of hypoxic response of CMS patients (n = 5 subjects) and non-CMS (n = 4 subjects) and 
sea-level (n = 3 subjects) control subjects. The graph depicts the relative proportion of CD235a quantified 3 wk after the administration of hypoxia (5% 
O2). There is a significantly striking difference between sea level, non-CMS, and CMS under hypoxia. ***, P < 0.001. Error bars represent the mean ± SEM 
of at least two to three measurements. The experiment was repeated at least three times. (C) Summary of interclonal variability among the subjects: three 
clones (clones 1, 2, and 3) were tested for three subjects (subjects 1, 2, and 3) for each group: CMS, non-CMS, and sea level. The y axis depicts the relative 
proportion of CD235a under hypoxia for different clones. Error bars represent the mean ± SEM of at least two to three measurements. (D) Dose response. 
The graph represents the response (as measured by proportion of CD235a [y-axis]) of CMS, non-CMS, and sea-level cells to 21%, 10%, 5%, and 1.5% O2 
levels (x axis). Each point depicts the mean ± SEM of at least two to three measurements. CMS shows hyperresponsiveness at 10, 5, and 1.5% O2. The 
experiment was repeated at least three times.
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Figure 3. characterization of the erythroid cells under normoxia and hypoxia. (A) CD analysis of various markers (CD45, CD71, and CD235a) for 
all populations under normoxia (21% O2). The cells are cultured as described in Fig. 1. Note that the CD profiles are similar for all groups under normoxia. 
(B) CD analysis of various markers (CD45, CD71, and CD235a) for all populations under hypoxia (5% O2). The cells were cultured as described in Fig. 1. During 
week 3, we see significant differences in the proportion of CD235a between CMS and the controls (sea level and non-CMS). (A and B) Each experiment was 
done in three replicates, and experiments were repeated at least three times. (C) BFU-e assay under hypoxia (5% O2). The y axis represents the number of 
BFU-e colonies. The experiment was done in three replicates and repeated twice. (D) Hemoglobin (Hb) analyses and function of erythroid cells with high- 
2735JEM Vol. 213, No. 12
lines (Fig. 4 E). Multiple clones of SENP1 knock-out showed 
a similar loss of phenotype (Fig. 4 E), affirming the critical 
role of SENP1 in the increased sensitivity of CMS to hypoxia. 
We also overexpressed SENP1 cDNA in the non-CMS iPSC 
lines (Fig. 4 F), and interestingly, the non-CMS cells (with 
overexpressed SENP1) show a similar polycythemic pheno-
type as the CMS cells (Fig. 4, F and G). Hence, by manipulat-
ing SENP1, we converted the CMS polycythemic trait into 
a non-CMS blunted response and vice versa. This proves our 
hypothesis that SENP1 plays a fundamental role in the CMS 
polycythemia of high altitude and the lack of this phenotype 
in the non-CMS population.
GAtA1 and Bcl-xL are differentially expressed  
in cMS and non-cMS cell lines
To further explore the underlying molecular mechanisms of 
the polycythemic phenotype in CMS subjects, we performed 
a cytokine reduction experiment in which we removed one 
of the eight cytokines and kept the rest (the other seven) in-
tact during the process of differentiating iPSCs. We found that 
removal of stem cell factor (SCF), BMP4, IL3, IL6, and Epo 
one at a time adversely affected the formation of RBCs in 
all three cell populations (Table 3), indicating that an exoge-
nous source was important for their development. However, 
removal of thrombopoietin (TPO), FLT3L, and VEGF from 
the medium of CMS cells did not change the marked eryth-
ropoietic response, unlike the sea-level and non-CMS cells, 
which were very affected, resulting in a nil response to hy-
poxia in these two populations of subjects. We then hypoth-
esized that either (a) CMS cells produce these factors (e.g., 
TPO) to compensate for those that are removed or (b) there 
is potentially a cross-talk between pathways that bypasses the 
need for these specific factors in CMS, unlike in the other 
two populations. Actually, our real-time PCR data showed 
that CMS subjects produce significantly higher VEGF (but 
not TPO or FLT3) in hypoxia (Fig. 5 A), with no change in 
VEGF, TPO, or FLT3 receptors. To determine whether there 
is a cross-talk between VEGF, TPO, and Flt3 signaling path-
ways, we tested the expression of downstream factors, such as 
GATA1, Bcl-xL, and STAT5 a,b. In fact, CMS cells produced 
significantly higher levels of Bcl-xL in hypoxia (Fig. 5 A) and 
copious amounts (>10-fold) of GATA1, as compared with 
the other cell populations (Fig.  5  A). This is also the case 
for CMS cells producing significantly higher GATA1 pro-
tein when compared with non-CMS cells (Fig. 5, A and B). 
These results became very informative because SENP1 stabi-
lizes GATA1 and leads to its up-regulation as well as the up- 
regulation of GATA1-responsive genes, e.g., Bcl-xL. Hence, 
we performed these experiments in CMS and non-CMS at 
the mRNA and protein levels. CMS cells produced signifi-
cantly higher levels of GATA1-inducible genes Slc4a1 and 
Alas2 than non-CMS cells (Fig. 5, C and D). In contrast, we 
observed higher expression of GATA1-repressive genes cMyc 
and cKit in non-CMS cells (Fig. 5, C and E).
SEnP1-mediated GAtA1 activation is essential  
for polycythemic response of cMS
SENP1-mediated desumoylation is considered to be a reg-
ulatory mechanism for the activation of transcription fac-
tors such as GATA1. When we tested the sumoylation levels 
of GATA1 in both CMS and non-CMS cells (EBs), we 
found that non-CMS had much higher levels of sumoy-
lated GATA1 as compared with CMS patients in hypoxia 
(Fig. 5 F). The relatively high levels of sumoylation of tar-
get genes under hypoxia is in accordance with a previous 
study by Jiang et al. (2015), where they observed higher 
levels of sumoylated HIF under hypoxia. We verified our 
finding by immunoprecipitation (IP) experiments and ob-
served significantly higher levels of GATA1 sumoylation in 
non-CMS samples as compared with CMS samples under 
hypoxia (Fig.  6, A and B). The SUMO-GATA1/GATA1 
ratios are significantly different between CMS and non-
CMS cells under hypoxia (Fig. 6 B; P < 0.01). These ratios 
are within the range of published mouse SENP1KO studies 
(Yu et al., 2010). To prove that increased hypoxia sensitivity of 
CMS cells is linked to SENP1-desumoylation GATA1 acti-
vation, we designed a fused SUMO-GATA1 construct using 
SUMO-fusion technology. The reason for using this con-
struct was to determine whether this fused SUMO-GATA1 
cannot be desumoylated by SENP1 and, hence, to directly 
test the function of SENP1 in the desumoylation and activa-
tion of GATA1. The overexpression of fused SUMO-GATA1 
in GATA1 knock-out background did not induce the CMS 
phenotype in hypoxia, suggesting that SENP1 is critical in 
activating GATA1 and the erythropoietic response under 
hypoxia (Fig.  6 C). It is important to note that the fused 
SUMO-GATA1 has reduced activity as measured by EPOR 
and cMyc levels (e.g., mean EPOR mRNA levels as mea-
sured by real-time PCR are 0.155 for CMS cells and 0.11 
for CMS cells containing fused SUMO-GATA1 construct; 
not depicted), but even with this level of reduced activ-
ity, GATA1 does not reestablish the CMS phenotype under 
hypoxia. However, when we overexpressed GATA1-K137R 
(which cannot be sumoylated) in GATA1 knock-out 
performance liquid chromatography profiles of erythroid cells at weeks 6 and 8. Note a shift in hemoglobin from fetal to adult A0. The O2-binding curve also 
shows a transition of P50 from 14 mmHg (week 6) to 22 mmHg (week 8). Shown is one representative image of data points at weeks 6 and 8. The experiment 
was repeated at least five times. A.U., arbitrary units; Sat, saturation. (E) Western blot of RBCs (erythroblasts). Note the presence of BAND-3 and GLUT1 in 
all lanes (normalized to actin). Retic, reticulocytes used as controls. (F) Globin expression by quantitative PCR for sea level and globin switching in time in 
culture. Similar trends were observed during maturation for all groups. n = 3 and error bars represent SD. Globin percentage is calculated as described by 
Qiu et al. (2008). The experiment was repeated at least three times. *, P < 0.05.
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background, we observed that both CMS and non-CMS 
showed an increased polycythemic response under hy-
poxia (Fig. 6 E). We verified the overexpression of the fused 
SUMO-GATA1 and GAT AK137R-mutant constructs by 
Western blotting (Fig. 6, D and F). Further, by overexpress-
ing the GATA1 target gene Bcl-xL, we only partially rescued 
the blunted response to hypoxia in non-CMS (Fig. 7, A and 
B). The non-CMS Bcl-xL overexpression line had signifi-
cantly higher erythropoietic response than uninfected non-
CMS (P < 0.05), but it was as much as the CMS line. The 
overexpression of Bcl-xL partially increased the proliferation 
capacity of erythroid progenitors in non-CMS as shown in 
Fig. 7 C. Collectively then, our data show that SENP1 acti-
vates GATA1 and downstream signaling pathways.
dIScuSSIon
Based on our previous work (Zhou et al., 2013) detailing 
the whole-genome analysis of high-altitude dwellers in the 
Andes, we had hypothesized that several candidate genes 
played a role in the extreme phenotype of polycythemia of 
CMS subjects. Taken differently, these potential candidates 
could have played an important role in blunting the response 
of non-CMS subjects to high-altitude hypoxia and, hence, 
in allowing these subjects to better adapt to high altitude. In 
fact, one question that arises from both our previous study 
(Zhou et al., 2013) and our current one is whether the non-
CMS subjects have adapted by a loss of function of SENP1 
(or potentially also other genes). It is at present a hypothe-
sis, and we do not have any such proof except that an up- 
regulation of SENP1 in hypoxia leads to the phenotype and 
its down-regulation to an absence of polycythemia. Another 
question that can be asked is the cause of the up-regulation 
of SENP1 during hypoxia in CMS subjects. Although this 
can be thought of as potentially an epigenetic phenomenon 
because it is linked to hypoxia exposure, it is not part of the 
scope of this work. Indeed, we have focused in this study 
on genetic mechanisms that are responsible for polycythemia, 
namely the response to SENP1 and its targets, particularly 
GATA1 and Bcl-xL, by both cell populations.
There were several reasons for choosing SENP1 (as a 
candidate gene) to understand the phenotype in CMS and 
non-CMS populations. First, we have previously shown that 
the expression of this gene is increased with hypoxia in CMS 
but not in non-CMS (Zhou et al., 2013); second, down- 
regulating its orthologue in flies dramatically enhances 
survival rates under hypoxia (Zhou et al., 2013); third, a 
null senp1 mutation in mice leads to embryonic lethality 
caused by anemia in mice (Yu et al., 2010); and finally, it 
has several desumoylation targets and hence may affect sev-
eral genes, transcription factors, and pathways (Cheng et al., 
2007). Herein, our work shows that SENP1 is central to 
erythropoiesis during hypoxia: an increase in SENP1 in-
creases remarkably the ability of non-CMS to form RBCs, 
and a down-regulation of SENP1 almost totally eliminates 
the exuberant response of the CMS to form RBCs during 
hypoxia. One could argue that because SENP1 has poten-
tially many desumoylation targets, it might not be surprising 
for SENP1 to have such a dramatic effect on response to 
hypoxia. However, to have only one gene, albeit a transcrip-
tion factor (e.g., GATA1), resulting (Fig. 6) in such a huge 
effect in eliminating erythropoiesis when desumoylated by 
SENP1 is clearly remarkable. On the one hand, it would not 
appear unreasonable to suspect that HIF would be involved 
in erythropoiesis in CMS subjects because SENP1 stabilizes 
HIF1α (Cheng et al., 2007) which regulates EPO expression 
and level. On the other hand, EPO, a downstream effec-
tor of HIF, has not been shown to be much different when 
CMS and non-CMS were compared (Dainiak et al., 1989; 
León-Velarde et al., 1991). In addition, we did not observe 
any significant difference in EPOR levels between the CMS 
and non-CMS in our in vitro model (EPOR mRNA lev-
els as measured by real-time PCR normalized by GAP DH: 
CMS is 0.155 ± 0.001 and non-CMS is 0.157 ± 0.001). 
Actually, by adding the same concentration of EPO in the 
media of the iPSCs of both cell populations, we removed in 
essence the effect of EPO in our phenotype. However, our 
current studies do not eliminate the effect of EPO in CMS 
subjects in vivo. Indeed, EPO is an essential mediator of 
erythropoiesis, and hence, further investigation is required 
to confirm its role in CMS (Villafuerte et al., 2014).
Conceptually, the reprogramming of fibroblasts into 
iPSCs and differentiation of these into RBCs is novel, espe-
cially when used for understanding high altitude–induced 
polycythemia using very unique and valuable populations 
that have adapted (or maladapted) to hypoxia for thousands 
of years (CMS vs. non-CMS populations). Our previous 
finding that SENP1 is a major candidate gene found in a 
selective DNA sweep in the Andean population was very 
Table 2. Efficiency of differentiation of rBcs under normoxia and hypoxia
Efficiency Sea level CMS Non-CMS
Normoxia
No. of EB cells/106 stem cells    1.08 ± (0.075)    0.92 ± (0.028) 1.19 (0.036)
No. of erythroid cells/106 stem cells   230 ± (0.16) 190 ± (0.2) 210 ± (0.16)
Hypoxia (5% O2)
No. of EB cells/106 stem cells    1.5 ± (0.68)    2.6 ± (0.28)    1.4 ± (0.036)
No. of erythroid cells/106 stem cells 270 ± (0.1)   310 ± (0.25) 166 ± (0.23)
The numbers in parenthesis represent SE. SE is for six experiments for each group. All values are 106 times.
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Figure 4. role of SEnP1 in cMS polycythemia in the Andean population. (A) The SENP1 region in Andean highlanders. Four known transcripts of 
human SENP1 with accession nos. (NCBI RefSeq) are shown. Note that SENP1 is transcribed from the negative strand (i.e., right to left). Overlaid above 
in blue are the genomic positions of 66 SNPs deemed differential by Zhou et al. (2013). Three of our differential SNPs (marked with black arrows) overlap 
with different regulatory regions such as promoters and enhancers, as described in the Critical role of SENP1 in polycythemia section of Results. These 
SNPs show a strong signal of frequency differentiation between the non-CMS and CMS highlanders, indicative of strong positive selection in the region. 
(B) Western blot analysis of SENP1 protein expression under hypoxia (5% O2) and normoxia (21% O2) for CMS and non-CMS groups. The representative blot 
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interesting. However, it is important to note that it is diffi-
cult to determine which of the 66 structural variants found 
to be differential between the populations is the casual vari-
ant. By using the haplotype allele frequency score (which 
some of us previously developed; Ronen et al., 2015), we 
could separate the carriers of the favored mutations from 
the noncarriers. From this haplotype allele frequency anal-
ysis, it is reasonable to conclude that the non-CMS carry a 
favorable mutation that decreases their predisposition to in-
crease erythropoiesis under hypoxia as in the CMS subjects. 
In this study, we confirmed the critical role of SENP1 and 
showed the role of specific targets in erythropoiesis in the 
CMS/non-CMS populations.
Although there have been studies in cell lines that sug-
gested that SENP1 regulates GATA1 (Yu et al., 2010), our 
study is the first to directly link Monge’s disease to GATA1 
activation through SENP1. That hypoxia-induced polycy-
themia of CMS subjects is not dependent on cytokines such 
as TPO and FLT3 is intriguing and new, especially that the 
non-CMS and sea-level subjects have a different response, 
indicating the involvement of different pathways for erythro-
poiesis in these populations. Our study opens a new avenue 
to study EPO-independent pathways linked to growth factors 
involved in erythropoiesis in humans.
Another possible mechanism for the differences seen 
among the CMS and non-CMS subjects is related to apopto-
sis and proliferation that could also be linked to SENP1 regu-
lation (Xu et al., 2015). Indeed, we see significant differences 
in the expression of the antiapoptotic gene Bcl-xL between 
CMS and non-CMS subjects. By overexpressing Bcl-xL in 
non-CMS cells, we can partially rescue the phenotype and 
make them comparable to sea-level individuals.
In conclusion, our study has shown that the exces-
sive polycythemic response in CMS subjects is an oligo-
genic trait and can be modeled in vitro using cutting-edge 
techniques. Functionally, we have established that SENP1 
plays a critical role in the differential erythropoietic re-
sponse of CMS and non-CMS subjects based on our ge-
netic studies whereby knock-down or overexpression of 
SENP1 can convert the CMS phenotype into that of non-
CMS and vice versa. The reduction experiments as well 
as the sumoylation differences in the GATA1 and fused 
SUMO-GATA1 experiments strongly suggest that GATA1 
is downstream of target of SENP1 and is involved in the 
polycythemia of this Andean population. Furthermore, 
decreased expression of the antiapoptotic gene Bcl-xL 
(GATA1 downstream effector) in the non-CMS cells is 
responsible in part for the blunted erythropoietic response 
under hypoxia particularly at the erythroid progenitor 
stage. We believe that the utility of this iPSC-derived hy-
poxia model of the Andean population that has lived in 
chronic hypoxia over thousands of years lies not only in 
the understanding of hypoxia-induced polycythemia, but 
also in other hypoxia-driven diseases experienced at sea 
level, as we have recently shown for the Ethiopian popula-
tion (Stobdan et al., 2015).
MAtErIAL And MEtHodS
Subjects and clinical characterization
All subjects were adult males residing in the Andean moun-
tain range in Cerro de Pasco, Peru at an elevation of ∼4,338 
m. Sea-level controls were adult individuals of similar age 
group who lived at sea level their entire life and have nor-
mal hematocrit and oxygen saturation. CMS patients fulfilled 
the diagnostic criteria for CMS, or Monge’s disease, based on 
their hematocrit, O2 saturation, and CMS score (>12). Each 
subject signed an informed written consent under protocols 
approved by the University of California, San Diego and the 
Universidad Peruana Cayetano Heredia.
Preparation of dermal fibroblasts from human skin biopsies
3-mm skin punch biopsy samples were obtained from male 
highlanders with CMS (n = 5) and without CMS (n = 4) 
in Cerro de Pasco, Peru, as well sea-level individuals (n = 3). 
The skin biopsies were mechanically dissociated and plated 
for dermal fibroblast expansion in DMEM supplement 
with 10% fetal calf serum, 2.5% penicillin/streptomycin, 
and 1% fungizone antibiotic (Invitrogen). Fibroblasts grew 
from explants after 2–3 wk and were passaged when they 
achieved 80% confluence.
is shown is from one experiment. The relative levels were computed for n = 5 for CMS and n = 4 for non-CMS under hypoxia and normoxia. Data represent 
at least two to three measurements. The experiment was repeated at least twice for each subject. (C) iPSCs were infected with lentivirus and selected by 
puromycin. shSENP1#1, shSENP1#2, and shSENP1#3 represent the three clones selected. Each clone showed significant down-regulation of Senp1 expres-
sion by quantitative PCR, compared with uninfected iPSCs, as well as an iPSC line infected by control vector. Data represent two measurements in duplicate. 
(D) Western blot analysis of the loss of SENP1 expression in the shRNA clones. Lanes 1 and 2 show significant reduction in SENP1 levels in shRNA clones 1 
and 2 as compared with uninfected and scrambled controls. Each bar represents the mean ± SEM of at least two to three measurements. The experiment 
was repeated at least two times for each subject. (E) Loss of vigorous erythropoietic response of CMS cells to hypoxia. The first bar represents the response 
of CMS cells to hypoxia. CMS-Senp1-shRNA represents the CMS cells that were infected by shRNA of Senp1 using lentivirus infection. Four different clones 
were tested for each line. Data represent three measurements in triplicates. The experiment was repeated three times. An unpaired Student’s t test was used. 
(F) Overexpression of SENP1 in non-CMS iPSCs. The blot shows a representative image for one experiment. We observed a twofold increase in expression in 
non-CMS in the cDNA overexpression cell line. Data represent three measurements in triplicates. The experiment was repeated twice. An unpaired Student’s 
t test was used. (G) SENP1 overexpression (OE) leads to marked increase in RBCs in non-CMS erythroid cell differentiation. The scrambled control overex-
pression did not change the phenotype of CMS. Each bar represents the mean for each clone measured in triplicates. The experiment was repeated three 
times. Error bars represent the mean ± SEM. *, P < 0.05; ***, P < 0.001.
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reprogramming of human fibroblast cells 
and generation of iPScs
Retroviral vectors containing the Yamanaka factors (OCT4, 
cMYC, KLF4, and SOX2 human cDNAs) were manufac-
tured by Salk Institute Gene Transfer, Targeting, and Thera-
peutics Core. We have switched now to footprint-free Sendai 
virus technology. Nonintegrated iPSCs are generated using 
SeV vectors encoding OCT3/4, SOX2, KLF4, and cMYC 
(CytoTune-iPS 2.0 Sendai Reprogramming kit) following 
the manufacturer’s protocol. In brief, infected fibroblast cells 
were cultured using a feeder-free method with Essential 8 
medium. Compact colonies containing iPSC colonies ap-
peared after 3 wk and were mechanically picked, transferred 
to a Matrigel-coated dish (BD), and expanded in mTeSR me-
dium (STE MCE LL Technologies; Zhao et al., 2015). Three 
clones were picked from each subject and were analyzed to 
assess the interclone variability.
characterization of iPScs
3 wk after transduction, compact iPSC colonies appeared. 
These were similar to human embryonic stem cells and 
were characterized by large nuclei and scant cytoplasm. 
The colonies were manually picked and cultured on the 
Matrigel-coated plates for expansion. Three clones were col-
lected from each individual subject. DNA was extracted from 
fibroblasts and iPSC lines using a DNase blood and tissue kit 
(QIA GEN) for the subsequent analysis. DNA-fingerprinting 
analysis and stem array, a high-resolution karyotyping, were 
performed by Cell Line Genetics. DNA-fingerprinting anal-
ysis confirmed that the obtained iPSC line was identical to 
parental somatic cell lines. Furthermore, all iPSC colonies had 
a normal karyotype (Zhao et al., 2015). To validate complete 
reprogramming, the following evidence was included: (a) pos-
itive staining for NAN OG and tumor-related antigen–1-81, 
(b) positive staining for alkaline phosphatase, (c) similar ex-
pression of prominent endogenous pluripotency genes such 
as OCT4, SOX2, cMYC, KLF4, NAN OG, and LIN28 was 
observed in iPSCs and H9 cells, (d) in vitro EB-mediated 
differentiation with expression of multilineage differenti-
ation markers including ectodermal markers (microtubule- 
associated protein 2 [MAP2] and paired box 6 [PAX6]), 
mesodermal markers (Msh homeobox 1 [MSX1] and α 
smooth muscle actin [α-SMA]), and endodermal markers 
(cytokeratin 8 [CK8] and CK18), and (e) the presence of ex-
ogenous reprograming factors in the genomic DNA of iPSCs 
but the expression of transgenes in the mRNA of iPSCs was 
low or undetectable (Zhao et al., 2015). These data suggested 
that iPSCs were pluripotent and have the ability to differen-
tiate into three germ layers in vitro.
Erythroid induction and differentiation
Human iPSC passages 9–20 were grown in Matrigel (BD)-
coated dishes supplemented with mTeSR media (STE MCE LL 
Technologies). The protocol for erythroid induction was 
adapted from a study by Kobari et al. (2012). For all subjects, 
the cultures were started with approximately 107 cells. Human 
iPSCs were differentiated by formation of EBs (hEB) during 
27 d in a liquid culture medium on the basis of IMDM (Bio-
chrom), 450 µg/ml holo human transferrin (Sigma-Aldrich), 
10 µm g/ml recombinant human insulin (Roche), 2 IU/ml 
heparin, and 5% human plasma in the presence of 100 ng/ml 
SCF, 100 ng/ml TPO, 100 ng/ml FLT3 ligand, 10 ng/ml rhu 
bone morphogenetic protein 4 (BMP4), 5 ng/ml rhu VEGF 
(VEGF-A165), 5 ng/ml IL-3, 5 ng/ml IL-6 (PeproTech), and 
3 U/ml Epo. Terminal differentiation was achieved by further 
culturing in sequential combination of cytokines as described 
by Kobari et al. (2012)
Hypoxia treatment
EBs were cultured for 1 wk at 37°C in 5% CO2 in air. After 
1 wk, the EBs were transferred to a hypoxic incubator set at 
37°C, 5% O2, and 5% CO2 for 3 wk. FACS analysis was done 
at day 28 at the EB stage. For the dose response experiment, 
1.5%, 5%, and 10% O2 levels were used.
BFu-e and cFu-e assay
FACS-sorted CD34+ cells were plated at a density of 105 cells 
per 35-mm dish combined with MethoCult H4034 Opti-
mum media and 2% FBS. Dishes were incubated at 37°C in 
an incubator with 5% CO2 and 5% O2 for 14 d, at which time 
colonies were scored for BFU-E and CFU–GEMM (granu-
locyte, erythrocyte, monocyte, megakaryocyte).
Flow cytometric analysis
EBs were dissociated using Accuatase Cell Dissociation reagent 
(Invitrogen), washed with PBS supplemented with 2% FBS, and 
filtered through a 70-µm cell strainer (Falcon; BD). Cells were 
treated with propidium iodide (Sigma-Aldrich) before analysis. 
Cells were stained with hCD45 (leukocyte common antigen), 
hCD71 (transferrin receptor protein 1), and hCD235a-PE 
(glycophorin A) from BD and analyzed by a FAC SCanto cell 
analyzer (BD) using FAC SDiva software (version 6.0; BD).
Table 3. reduction experiment eliminating one cytokine at a time 
from the cytokines added to the cells
Factor reduction (−) CMS Non-CMS Sea level
SCF     0.2      0      0
TPO     31.1      0      0.1
Flt3     31.5      0      0
BMP4     0.1      0.1      0
VEGF     68.8      0      0
IL-3     2.3      0.1      0.6
IL-6     1.4      0.1      0.2
Epo     0.1      0      0.1
Relative proportion of CD235a marker after 3 wk under hypoxia eliminating one factor at a 
time. Eliminated cytokines are shown in column 1 for each experiment. The numbers under 
each population represent relative percentages of CD235a. The relative levels of CD235a in 
all populations with all factors in the media range in CMS (36–91.6%), non-CMS (0.2–1%), 
and sea level (3.1%–9.1%) are shown. Example: When TPO is eliminated in culture, 31.1% 
of cells (for CMS) were CD235a positive; for non-CMS and sea level, it was nil. Hence, CMS 
cells do not need TPO but sea-level and non-CMS cells do.
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Hemoglobin analysis and oxygen-binding assay
Hemoglobin fractions were separated and quantified by ion ex-
change high-performance liquid chromatography. Oxygen equi-
librium curves were obtained by deoxygenating O2-equilibrated 
samples in Hemox buffer at 37°C using a Hemox analyzer (TCS 
Scientific Corp). After thorough deoxygenation under nitrogen, 
the cell suspensions were equilibrated at different partial pres-
sures of oxygen by slow bubbling 40% oxygen into the cuvette. 
The fractional saturation was estimated by simulation of the ab-
sorption spectra in the visible regions as a linear combination of 
the fully deoxygenated and oxygenated spectra of the cells sus-
pension. The globin fractions were calculated by real-time PCR 
using the method described by Qiu et al. (2008).
Sumoylation assay using an ELI SA-based kit
Cytosolic and membrane proteins were isolated using stan-
dard protein isolation protocols and kits (Abcam). Relative 
sumoylation levels under hypoxia were measured using an In 
Vivo Protein Sumoylation Assay Ultra kit (EpiQuik). It is a 
calorimetric-based measurement, whereby the ratio or inten-
sity of the sumoylation, which is proportional to the conju-
gated SUMO amount, can be quantified through the signal 
report–color development system. Anti-GATA1 and anti–
SUMO-1 antibodies were purchased from Abcam. The per-
cent sumoylation was measured using the following formula: 
% Sumoylation = OD (Hypoxia sample − Negative control)/
OD (Normoxia sample − Negative control) × 100%.
Figure 5. Significant difference in expression between 
cMS versus non-cMS and sea-level cells. (A) Relative 
VEGF, GATA1, and Bcl-xL expression by quantitative PCR (nor-
malized with GAD PH) in cultures grown in hypoxia in media. 
CMS cells produced significantly higher levels of VEGF, GATA1, 
and Bcl-xL. (B) Western blot analysis of GATA1 protein levels. 
The figure shows a representative blot for one experiment. 
The bars shows the relative levels for n = 4 for each group 
(CMS and non-CMS). The experiment was repeated at least 
three times. An unpaired Student’s t test was performed. 
(C) Relative mRNA levels of GATA1-inducible (Scl4a and Alas2) 
and repressive (cMyc and cKit) genes for CMS and non-CMS 
subjects. (D) Western blot analysis of Alas2 protein levels. 
The figure shows a representative blot for one experiment. 
(E) Western blot analysis of cMyc protein levels. The figure 
shows a representative blot for one experiment. (C–E) The bars 
show the relative levels for n = 4 for each group (CMS and 
non-CMS). The experiment was repeated at least three times. 
An unpaired Student’s t test was performed. (F) Non-CMS 
cells show significantly high amount of sumoylated GATA1 
as compared with CMS and sea-level controls. P < 0.05; un-
paired Student’s t test. The results are the summary for n = 
4 for both CMS and non-CMS groups. Each bar represents 
the mean, and error bars represent the SE. For each sample, 
the levels were measured in triplicates. Each experiment was 
repeated three times. *, P < 0.05; **, P < 0.01.
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IP, immunoblotting, and sumoylation ratios
Cytosolic and membrane proteins were isolated using stan-
dard protein isolation protocols and kits (Abcam). IP was per-
formed using an IP kit (Thermo Fisher Scientific) following 
the procedure described by Yu et al. (2010). IP was performed 
using an anti-SUMO antibody (Abcam) followed by Western 
blot analysis using anti-GATA1 antibody. Primary antibodies 
against SENP1, GAP DH, and GATA1 were obtained from 
Santa Cruz Biotechnology, Inc. Antibodies against BAND3, 
GLUT1, SUMO1, CMYC, and ALAS were obtained from 
Abcam. In brief, 20 µg of lysate supernatant were separated by 
10% SDS-PAGE and transferred to a nitrocellulose membrane. 
The blots were developed using enhanced chemilumescent 
reagents (Bio-Rad Laboratories) and the ChemiDoc XRS+ 
molecular imager (Bio-Rad Laboratories).
reduction experiment for cytokines (ScF, tPo, FLt3, BMP4, 
VEGF, IL3, IL6, and EPo)
EBs were treated with eight different cytokines. Each mixture has 
one cytokine missing at a time (eight cytokines minus one cyto-
kine). EBs were transferred to hypoxic conditions as described in 
the Hypoxia treatment section and analyzed after 3 wk by flow 
cytometry as mentioned in the Flow cytometric analysis section.
real-time Pcr for VEGF, FLt3,  
and tPo reduction experiments
EBs were extracted from the culture media after weeks 1, 2, and 
3 in hypoxia. RNA was isolated from EB using an RNeasy 
Mini kit (QIA GEN). cDNA was produced from total RNA 
through RT-PCR using a Superscript III First-Strand Synthe-
sis system (Invitrogen). Real-time PCR was performed using a 
GeneAmp 7900 sequence detection system using POW ER 
SYBR Green chemistry (Applied Biosystems). The primer se-
quences were as follows: VEGF165-L, 5′-ATC TTC AAG CCA 
TCC TGT GTGC-3′; VEGF165-R, 5′-CAA GGC CCA CAG 
GGA TTT TC-3′; Vegf-A(all isoforms)F, 5′-GAG ATG AGC 
TTC CTA CAG CAC-3′; Vegf-A(all isoforms)R, 5′-TCA CCG 
CCT CGG CTT GTC ACAT-3′; FLT3-F, 5′-TTT CAC AGG 
ACT TGG ACA GAG ATTT-3′; FLT3-R, 5′-GAG TCC GGG 
TGT ATC TGA ACT TCT-3′; TPO-F, 5′-CAG GAC TGA AAA 
Figure 6. SEnP1 desumoylase activity plays a criti-
cal role in GAtA1 desumoylation and activation. (A) A 
representative blot showing that non-CMS cells show sig-
nificantly higher levels of sumoylated GATA1. The sumoy-
lated form of GATA1 was determined by IP with anti-SUMO 
followed by Western blotting with anti-GATA1. The ratios 
of SUMO-GATA1/GATA1 were quantified. IB, immunoblot. 
(B) Non-CMS cells show a significantly high SUMO-GATA1/
GATA-1 ratio as compared with CMS. P < 0.05; Student’s t 
test. The results are the summary for n = 4 for both CMS and 
non-CMS groups. Each bar represents the mean, and error 
bars represent SE. For each sample, the levels were measured 
in triplicates. Each experiment was repeated three times. 
(C) Fused SUMO-GATA1 cannot restore the remarkable CMS 
phenotype in a background of GATA1 KO. Non-CMS had a sim-
ilar result. Each bar represents a mean of three replicates, and 
the experiment was repeated at least twice. (D) Western blot 
analysis confirming significantly higher levels of SUMO-fused 
Gata1 in the overexpressed (OE) line. Lane 1 represents CMS 
cells lines overexpressing fused SUMO-GATA1 in the GATA1 
KO background. Please note the significantly higher levels of 
SUMO-GATA1 in the GATA1 KO background. Lane 2 shows the 
relative levels of SUMO-GATA1 and GATA1 in non-CMS cells. 
Lane 3 shows the relative levels of SUMO-GATA1 and GATA1 
in CMS cells. (E) GAT AK137R (GATA1KR) mutant causes the 
polycythemic phenotype in both CMS and non-CMS subjects 
under hypoxia. Each bar represents a mean of three replicates, 
and the experiment has been repeated at least twice. (F) West-
ern blot analysis showing overexpression of GATA1K137R in 
the non-CMS cells. Lane 1 represents non-CMS cell lines over-
expressing GATA1K137R in the GATA1KO background. Lane 2 
shows the relative levels GATA1 in uninfected CMS cells. Lane 
3 shows the relative levels of GATA1 in uninfected non-CMS 
cells. (C–F) Each bar represents the mean of three replicates, 
and the experiment was repeated at least twice. Error bars 
represent SEM. **, P < 0.01.
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GGG AAT CA-3′; TPO-R, 5′-CGT TGG AAG GCC TTG 
AAT TT-3′; GATA1-L, 5′-CCT GCT TTG TTG CCA ATG-3′; 
GATA1-R, 5′-CTG CTC CAC TGT TAC GGA TAC-3′; Bcl-
xL-L, 5′-GCA GGT ATT GGT GAG TCG GAT CGC-3′; and 
Bcl-xL-R, 5′-CAC AAA AGT ATC CCA GCC GCCG-3′. The 
expression level of GAD PH was used to normalize the results. 
GAD PH-L, 5′-CTGGCA TTG CCC TCA ACG ACC-3′ and 
GAD PH-R, 5′-CTT GCT GGG GCT GGT GGT CC-3′.
Lentiviral vectors and transduction of iPScs 
for knock-down of Senp1
The shRNA-SENP1 construct was a gift from G. Salvesen’s 
laboratory (Sanford-Burnham Prebys Medical Discovery 
Institute, La Jolla, CA). Human SENP1 and Bcl-xL (open 
reading frame) in an expression-ready lentiviral system con-
struct was purchased from GE Healthcare. The packaging 
and lentivirus generation was done by Salk Institute Gene 
Transfer, Targeting, and Therapeutics Core. Transduced cells 
were selected at 0.5 µg/ml puromycin (Sigma-Aldrich) or 
blasticidin (EMD Millipore). The expression of SENP1 was 
confirmed by real-time PCR.
Generation of GAtA1 Ko and 
fused SuMo-GAtA1 constructs
GATA1 KO construct was generated with blasticidin resis-
tance by Gentarget. The fused SUMO-GATA1 construct 
was generated by Lifesensors, and the construct was sub-
cloned, and the lentivirus was generated by ViGENE. Trans-
duced cells were selected at 0.5–1 µg/ml blasticidin (EMD 
Millipore) and 0.5 µg/ml puromycin (Sigma-Aldrich). 
GATA1K137R construct was a gift from W. Min’s (Yale Uni-
versity, New Haven, CT) and C. Santoro’s (Interdisciplinary 
Research Center on Autoimmune Diseases, Novora, Italy) 
laboratories. This construct was subcloned, and the lentivirus 
was generated by ViGENE. Transduced cells were selected for 
1 µg/ml puromycin (Sigma-Aldrich).
Statistical tests
One-way ANO VA followed by Tukey posthoc analysis was 
used to test significant differences between the subjects of 
each group (CMS, non-CMS, and sea level), as well as to as-
sess interclonal variability. Student’s t tests were performed to 
evaluate differences between the various groups.
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